CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
This Quarter Return
+11.72%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$249M
AUM Growth
+$249M
(+4.7%)
Cap. Flow
+$8.57M
Cap. Flow
% of AUM
3.45%
Top 10 Holdings %
Top 10 Hldgs %
35.47%
Holding
513
New
48
Increased
267
Reduced
44
Closed
122
Top Buys
| 1 |
iQIYI
IQ
|
$12.8M |
| 2 |
Amazon
AMZN
|
$3.31M |
| 3 |
uniQure
QURE
|
$3M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$2.97M |
| 5 |
DexCom
DXCM
|
$2.87M |
Top Sells
| 1 |
Novo Nordisk
NVO
|
$3.65M |
| 2 |
Tesla
TSLA
|
$3.64M |
| 3 |
Procter & Gamble
PG
|
$3.53M |
| 4 |
Nike
NKE
|
$3.17M |
| 5 |
CVS Health
CVS
|
$2.99M |
Sector Composition
| 1 | Technology | 35.23% |
| 2 | Healthcare | 25.2% |
| 3 | Consumer Discretionary | 20.47% |
| 4 | Communication Services | 8.05% |
| 5 | Financials | 3.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
NovoCure
NVCR
$1.38B
| $78.2K | 0.03% |
1,066
+85
| +9% | +$6.24K |
|
127
Carnival Corp
CCL
$43.2B
| $77.2K | 0.03% |
9,580
-14,500
| -60% | -$117K |
|
128
Amphenol
APH
$133B
| $76.3K | 0.03% |
+1,000
| New | +$76.3K |
|
129
Ascendis Pharma
ASND
$11.8B
| $69.2K | 0.03% |
567
+47
| +9% | +$5.74K |
|
|
KRTX
130
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $68.6K | 0.03% |
349
+31
| +10% | +$6.09K |
|
131
Medpace
MEDP
$13.4B
| $67.1K | 0.03% |
316
+26
| +9% | +$5.52K |
|
132
Guardant Health
GH
$8.41B
| $66.3K | 0.03% |
2,436
+84
| +4% | +$2.29K |
|
133
Roivant Sciences
ROIV
$8.15B
| $58.9K | 0.02% |
+7,369
| New | +$58.9K |
|
134
Apellis Pharmaceuticals
APLS
$3.48B
| $58.1K | 0.02% |
1,123
+94
| +9% | +$4.86K |
|
135
Ionis Pharmaceuticals
IONS
$6.8B
| $54.5K | 0.02% |
1,443
+114
| +9% | +$4.31K |
|
136
Exelixis
EXEL
$10.1B
| $52.6K | 0.02% |
3,277
+263
| +9% | +$4.22K |
|
|
ITCI
137
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $50.9K | 0.02% |
962
+78
| +9% | +$4.13K |
|
138
Madrigal Pharmaceuticals
MDGL
$9.76B
| $50.5K | 0.02% |
174
-2,424
| -93% | -$704K |
|
|
RXDX
139
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $46.9K | 0.02% |
426
+43
| +11% | +$4.73K |
|
140
Cytokinetics
CYTK
$4.23B
| $44K | 0.02% |
961
-27,087
| -97% | -$1.24M |
|
141
Arrowhead Research
ARWR
$3.05B
| $43.7K | 0.02% |
1,077
+85
| +9% | +$3.45K |
|
142
Alkermes
ALKS
$4.78B
| $43.6K | 0.02% |
1,669
+131
| +9% | +$3.42K |
|
143
ZTO Express
ZTO
$14.6B
| $43K | 0.02% |
+1,600
| New | +$43K |
|
144
Vaxcyte
PCVX
$4B
| $38.5K | 0.02% |
803
+248
| +45% | +$11.9K |
|
145
Denali Therapeutics
DNLI
$2.23B
| $38.4K | 0.02% |
1,380
+225
| +19% | +$6.26K |
|
|
SYNH
146
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $38.3K | 0.02% |
1,045
+84
| +9% | +$3.08K |
|
147
Beam Therapeutics
BEAM
$1.66B
| $37.2K | 0.02% |
952
+57
| +6% | +$2.23K |
|
148
Amicus Therapeutics
FOLD
$2.34B
| $34.8K | 0.01% |
2,854
+227
| +9% | +$2.77K |
|
149
Vir Biotechnology
VIR
$686M
| $34.2K | 0.01% |
1,353
+111
| +9% | +$2.81K |
|
150
Axsome Therapeutics
AXSM
$6.05B
| $34K | 0.01% |
441
+64
| +17% | +$4.94K |
|